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Summary: In this study, the levels of the cysteine proteinase - cathepsin B were measured in diseased synovial
fluids using a steady state fluorometric assay. Cathepsin B-like activity was shown to be present in all the samples
analysed, with the rheumatoid arthritic synovial fluids possessing significantly higher concentrations (mean value
ca. 416 mg/1) than the osteoarthritic fluids (mean value ca. 142.4 mg/1). In addition, upon treatment with pepsin, all
of the rheumatoid arthritis samples were shown to possess additional cathepsin B-like activity, suggesting the
presence of a reservoir of latent precursor molecules. By utilising a recently developed biotinylated affmity label
for cathepsin B-like proteinases and sheep anti-(human cathepsin B) antibodies, used in combination with SDS-
PAGE and Western blotting, the rheumatoid arthritic synovial cathepsin B was shown to exist in two forms with
apparent molecular masses of Mr 29 000 and 42 000. We propose that the former is a ftmctionally active proteinase,
whereas the latter is a pepsin activatable proform which, when cleaved by this aspartyl proteinase, is converted into
a catalytically competent species of Mf20000.
Introduction
Arthritis encompasses almost 200 different illnesses, of
which osteoarthritis and rheumatoid arthritis are the
mpst widespreäd. With the limited availability of bio-
chemical markers, early diagnösis is almost impossible
and referräl, to the clinic is usually the result of the
patient experiencing paiü, stiffiiess and loss of joint
function. In a large majority of patients, the disease has
progressed to such a degree, that the önly remaining
remedial action of total joint replacement. In the ma-
jority of the main classes of arthritic disease such äs
osteoarthritis and rheumatoid arthritis, there is massive
degradation of the articular cärtilage - the cushion in
the synovial joint - causing the increase in pain and
loss of joint function (!)·. Much attention has been di-
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rected towards identifying those agents that are capable
not only of bringing about such destruction of the articu-
lar surfaces, but also of the synovial fluid, the mechan-
ical properties of which are also known to deteriorate
with disease (1). One class of agents thought to be cap-
able of such degradation are the proteinases and, in par-
ticulär, much attention has focused on the possible in-
volvement of the cysteine proteinases in arthritic dis-
ease (2).
It is known, for example, that cathepsin B is secreted
from rheumatoid synoviocytes into the synovial fluid
and thus naay be involved in the in vivo degradation of
connective tissue proteins (2). This thesis seems all the
more reasonable in light of the in vitro studies demon-
strating that cathepsin B can degrade various connective
tissue constituents such äs collagen and proteoglycans
(3-5). Under nonnal circumstances, any cathepsin B
that is secreted/released into the synovial fluid is ef-
ficiently neutralised by proteinaceous inhibitors such äs
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haptoglobulin and a2-macroglobulin (6), three α\ and a2
thiol protease Inhibitors (7-9) and the cystatins such s
cystatin C (10). In contrast, in diseased conditions, an
imbalance is thought to exist between proteinase and
inhibitor - in favour of the former, and the proteinases
are free to degrade the articular cartilage and other tis-
sues in the joint (11). Other studies have demonstrated
the possible therapeutic value of developing selective
cathepsin B inhibitors based on the peptidyl fluoro-
methyl ketones (12, 13).
It is against this background that we have undertaken
this present study on the detection, quantification and
partial characterisation of cathepsin B-like proteinases
in the synovial fluid of patients suffering from osteoar-
thritis and rheumatoid arthritis. This has been achieved
by a combination of methods including steady-state
fluorimetric assays and a recently developed Western
blotting technique utilising a biotinylated afFmity label
for cathepsin B-like proteinases (14, 15).
Materials and Methods
Sample collection
In order to analyse the enzymatic properties of synovial fluid,
samples were collected from patients, who were undergoing joint
replacement surgery at Musgrave Park Hospital Belfast, and also
from patients at the Rheumatology Outpatient Clinic, Belfast City
Hospital, Belfast. Diagnosis was determined according to the cri-
teria outlined by the American Rheumatism Association (16). All
samples were obtained in undiluted form immediately prior to sur-
gical procedures. In addition, the relevant medical Information and
history was obtained, by the surgeon, in an accompanying pro-
forma with each sample. The proforma was designed not only to
assist in the diagnosis but to provide the raedical Information to
explain the results in terms of the pathogenesis of the joint disease.
Synthesis of affinity labels
The diazomethane afFmity labels, N-benzyloxycarbonyl-phenylala^
nyl-alanine-diazomethane (Cbz-Phe-Ala-CHN2)2) and N-benzyl-
oxycarbonyl-phenylalanyl-tyrosine(OBut)-diazomethane (Cbz-
Phe-Tyr-(OBut)-CHN2) were prepared by the general procedures
(17, 18) and had melting points in close agreement with the litera-
ture values (19). The biotinylated affinity label N-biotinyl-phe-
nylalanyl-alanine-diazomethane (Bio-Phe-Ala-CHN2) was pre-
pared by the cited procedure (14).
Sample preparation
Each of the samples was centrifuged at 5000 g for 30 min in order
to remove any contaminants such s blood and debris associated
with the surgical Operation. The supernatant was then stored at
-15 °C prior to utilisation in the enzymatic analysis.
Steady state assay
.Samples of synovial fluid were assayed for cathepsin B-like ac-
tivity s described by Barren & Kirschke (20). In essence, samples
2) Abbreviations used
Bio, biotinyl; Cbz, benzyloxycarbonyl; Mee, 4-methylcoumarin-7-
yl; OBut, f-butyl ether.
(50 μΐ) were added to a solution of (l ml) N-benzyloxycarbonyl-
argmyl-arginyl-4-methylcoumarin (Cbz-Arg-Arg-NH-Mec) (Ba-
chern, Bubendorf, Switzerland) (50 μιηοΐ/ΐ) in 100 mmol/l sodium
phosphate buffer, pH 6.4 containing l mmol/l ethylenediaminete-
traacetic acid disodium salt, 10 g/I Brij 35 and 2 mmol/I cysteine,
maintained at 37 °C. The rate of hydrolysis was monitored continu-
ously by mcasuring the rate of increase in fluorescence at 455 nm
(excitation wavelength 383 nm) in a Perkin-Elrner MPF 44B spec-
trofluorimeter. This Substrate is hydrolysed by cathepsin B but not
cathepsins H or L (20). However, since kallikrein is known to de-
grade this Substrate (21), control assays were carried out in the
presence of the active-site-directed inhibitor Cbz-Phe-AIa-CHN2,
which inactivates cysteine- but not serine proteinases (22).
Pepsin activation
As pepsin-activatable precursor forms of cathepsin B-like protein-
ases have been detected in such fluids s ascitic fluid from patients
with ovarian cancer (23, 24) and in medium conditioned by tumour
breast cancer cells in culture (15). The activation protocol de-
scribed by these workers was applied to the synovial fluid samples
in order to reveal any latent cathepsin B precursors that may have
been present. Synovial fluid samples were treated with pepsin
(Sigma, final concentration: 20 mg/1), in 0.1 mol/1 glycine/HCl
buffer pH 3.0, at 37 °C. The resulting activity was then determined
by a steady state assay measuring the turnover of the fluorogenic
Substrate Cbz-Arg-Arg-NH-Mec. The hydrolysis of the Substrate
was blocked by Cbz-Phe-Ala-CHN2. Time course studies revealed
that maximum cathepsin B-like activity was generated after 60 mi-
nute exposure to pepsin. In the absence of pepsin, no activation of
latent enzyme was observed in any f the samples studied.
Characterisation of labelled proteinases
Labelling of proteinases
To 0.5 ml of centrifuged synovial fluid was added 0.5 ml of 100
mmol/l phosphate buffer, pH 6.4, containing 2 mmql/l cysteine,
l mmol/l ethylenediaminetetraacetic acid disodium salt and 10 g/l
Brij 35. Ten μΐ of Bio^Phe^Ala-CHN2 (l mmol/l in methanol) were
added to this, and the solution was then incubated for two hours
at room temperature. Following this, 0.5 ml of 400 g/l trichlo-
roacetic acid was added to precipitate out the proteinaceous mater-
ial, the mixture was then centriftiged for 15 min at 5000g and the
supernatant was discarded. The pellet was then dissolved in 0.5 ml
ofLaemmli treated buffer and then boiled for 10 min thus terminat-
ing the feaction between the enzyme and inhibitor.
Electrophoresis
One dimensional SDS electrophoresis was performed (25) with
10% slab gels run at a constant cujrrent of 30 mA using the Mighty
Small II Apparatus (Hoefer Scientific). Biotinylated molecular
weight Standards (Sigma Chemicals, Poole, Dorset, UK) were em-
ployed on each geh
Western blotting
Transfer of protein from gel to nitrocellulose (pore size: 0.2 mm;
Schleicher und Sch ll, Dassel, Germany) was carfied put by the
cited method (26). The protein transfer was. carried out in 25
mmol/l glycine/192 mmol/l Tris/200 g/l methanol using a Transr
Biot Celt (Βίο-Rad). The running time was 18 h at 100 mA, with
a constant ternperature of 4 °C. ..·,
Detection of labelled proteins
"The nitrocellulose blot was staiaed for biotinylated proteins by
overlaying with streptavidin/ lkaline phosphatase. The nitrocellu-
lose paper was firstly .blocked by dhtubation for 30 -min with a
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50 g/l solution of bovine serum albumin (Sigma) containing l g/l
merthiolate and l g/l anti-foam agent (Sigma). Streptavidin/alka-
line phosphatase (Vector Laboratories), diluted 1 : 1000 in blocking
solution, was incubated with the nitrocellulose blot at room tem-
perature for 2 -4 h with agitation. The blot was then washed at
least six times with 0. l mol/1 Tris/HCl, pH 9.5, containing 0. l mol/1
NaCl and 5 mraol/1 MgCl2 before the alkaline phosphatase activity
was detected by using Nitro Blue Tetrazoliura (66 ml of a 75 g/l
solution in 700 g/i , -dimethyl formamide/H2O) and 5-bromo-4-
chloro-indol-3-yl phosphate (33 ml of a 50 g/l solution in N,N-
dimethyi formamide) in 10 ml of the same buffer.
Innnunobloläng
The proteinaceous precipitate from samples of synovial fluid not
exposed to the biotinylated probe were subjected to electrophoresis
and Western blotting äs" described for the biotinylated proteins.
Antibody probing of the Western blots was then carried out (27).
Sheep anti-human cathepsin B IgG (Serotec; used at l : 200 di-
lution) and donkey anti-sheep IgG conjugated to alkaline phospha-
tase (Serotec; used at l : 1000 dilution), were used äs first and
, second antibodies respectively. Alkaline phosphatase activity was
, detected using Nitro Blue Tetrazolium and 5-bromo-4-chloroindol-
! 3-yl phosphate.
Results and Discussion
Comparison of cathepsin B levels in rheuma-
toid- and osteoarthritic synovial fluids
JBy measuring the rate of hydrolysis of the fluorogenic
:
 Substrate Cbz-Arg-Arg-NH-Mec, cathepsin B-like ac-
tivity was quantified in the synovial fluid of patients
with various arthropathies. This activity could be com-
pletely inhibited by the general cysteine protease inhibi-
tor iodoacetamide and, additionally, the activity was also
inhibited by the broad spectrum affinity label for cyst-
eine proteinases Cbz-Phe-Ala-CHN2 (22), but not by the
specific cathepsin L inhibitor Cbz-Phe-Tyr(OBut)-CHN2
(19). The exhibited inhibitor susceptibility taken in con-
sideration with the specificity of the Substrate (Cbz-Arg-
Arg-N£UMec), suggests that the observed activity was
indicative of a cathepsin B-like proteinäse and excludes
the possibility that a ksdlikrein^like enzyme is respon-
sible for the observed Substrate hydrolysis.
The levels of active cathepsin B (mg/1) were calculated
for each sample ässäyed, by refefence to a Standard solu-
tion of human cathepsin B - titrated against E-64 (20),
and were then categorised by disease group (see fig. 1).
Cathepsin B activity was detected in all synovial fluid
samples studied, regardless of the disease process. Stat-
istical analysis of these results was carried out using a
statistical analysis package, SPSS for Windows 6.0
(SPSS Inc., USA). Both rheumatoid arthritis and osteo-
arthritis subgroups exhibited normal Ganssian distri-
butions with the mean concentrations of cathepsin B
shown to be significantly higher in rheumatoid arthritic
synovial fluids (mean value 416 ± 226 mg/1) than in
osteoarthritic fluids (mean value 142 ± 80 mg/l), where
Eur. J. Clin. Chem. Clin. Biochem. / Vol. 32, 1994 / No. 6
3000
'53
2000·
1000
6 11 16
No. of samples
21 26
Fig. l Levels of cathepsin B-like activity in osteoarthritic (*) and
rheumatoid arthritic (O) synovial fluids.
p < 0.001 (28). Within the rheumatoid arthritis sub-
group, the large associated Standard deviation can larg-
ely be attributed to two statistical outlying samples, that
contain enormously high amounts of the proteinase
(1269 ± 29 mg/1, 2048 ± 25 mg/1), however, even with
these out-lying values excluded, the mean value for the
rheumatoid arthritic samples (320 mg/1) is still signifi-
cantly greater than that of the osteoarthritic samples.
Discriminant analysis of the cathepsin B levels revealed
a 72% correct classification by disease subgroup high-
lighting the potential of this steady state assay äs a diag-
nostic tool. Such results are in general agreement with
other workers who, by using ELISA (11) and radioim-
muno assay techniques (29), also found, on average, that
cathepsin B levels were higher in rheumatoid arthritic-
when compared with osteoarthritic synovial fluids and
sera.
A possible explanation for these findings can be found
in the observation that Cathepsin B has been detected in
the synovial membrane where it is thought to originale
from synoviocytes (30, 31). The higher levels of cathep-
sin B in rheumatoid arthritic synovial fluid may there-
fore be attributed to the fact that the disease is, unlike
osteoarthritis, inflammatory in nature and inflammation
of the synovial membrane may cause an increase in the
protease secretory Output of the synoviocytes. Addition-
ally, inflammation of the synovium may also cause an
influx of such cells äs macrophages which may also be
responsible for the secretion of cathepsin B and other
proteases into the synovial fluid. It is known, for ex-
ample, that collagenase levels are elevated in diseased,
particular inflammatory, conditions again suggesting
that proteolytic degradation may play an important role
in arthritic disease (32). Cathepsin B has also been
identified by other workers in rheumatoid synovial fluid
(31) and also in synovial fluid with various forms of
arthritis (33), using immunochemical methods.
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Western blot ana lys is of cathepsin B using
Bio-Phe-Ala-CHN2
To more fully characterise the activity present in the
diseased synovial fluid, samples that had been incubated
with the biotinylated affinity label Bio-Phe-Ala-CHN2
were subjected to SDS-PAGE on 10% slab gels, äs de-
tailed in the Materials and Methods section. This affinity
label has been demonstrated to react covalently at the
active-site of bovine and human cathepsin B, thüs en-
abling their detection — following Western blotting, by
utilising various streptavidin/enzyme labels (14, 15). Ut-
ilising this methodology, we were able to detect two
major bands of apparent MT 42000 and 29000 (flg. 2,
lane 3). The lower molecular weight form migrates with
the same mobility äs active lysosomal cathepsin B (20),
and is in accordance with values reported by other work-
ers, who have also identified a specific band of MT
29000 in synovial fluid (11).
Since thjs^ biotinylated affinity label has been demon-
strated to inactive both cathepsin B and L (34), it is
necessary to carry out pre-incubation experiments with
specific inactivators of cathepsin L that will block the
incorporation of the biotinylated probe into this protein-
ase thus enabling one to unambiguously identify läbelled
bands äs being cathepsin B-like. When samples of rheu-
matoid arthritic synovial fluid were pre-treated with
Cbz-Phe-Tyr(OBut)-CHN2 (0.1 mmol/1, for 30 min at
37 °C) which is just such an inactivator (19), no dimu>
ution in the incorporation of the biotinylated probe was
observed (compare lane 5 - pre-treated sample with
Mr
-97 400
-58100
-39 800
-29 000
-20100
-14 300
1 2 3 4 5 6 7
Fig. 2 Western blot of synovial fluid samples utilising biotiny^
lated affinity labels.
Lane l synovial fluid - pepsin activated, probed with anti-(ca-
thepsin B) antibody
Lane 2 synovial fluid probed with anti-(cathepsin B) antibody
Lane 3 synovial fluid pretreated with Biotin-Phe-Ala-CHN2
Lane 4 synovial fluid - pepsin activated, pretreated with Biotin-
Phe-Ala-CHN2
Lane 5 synovial fluid pretreated with Cbz-Phe-Tyr(OBut)-CHN2
and Biotin-Phe-Ala-CHN2
Lane 6 synovial fluid pretreated with Cbz-Phe-Ala-CHN2 and°
Biotin-Phe-Ala-CHN2
Lane 7 biotinylated molecular weight markers
lane 3 — no pre-treatment). This further strengthens our
case that the species of MT 42 000 and 29 000 are cathep-
sin B-like. In addition earlier studies have shown that
human cathepsin B-<x2-macroglobulm complexes were
not detectable with this biotinylated probe (unpublished
fesults) therefore it is unlikely'diat the steady state assay
was detecting such complexes. Moreover, we consider it
likely that the species of 29 000 is the active pfotein-
ase which is detected in the steady state assay and the
MT 42 000 form is possibly a pro-form of this proteinase.
We have previously observed a similar banding pattern
for a cathepsin B-like species produced by human breast
cancer cells in culture (15) and in this particular instance
the high molecular weight species coüld be converted,
via activation with pepsin, irito a 29 000 form capable
of cleaving the fluorogenic Substrate (Cbz-ArgrArg-·
NH-Mec.
In order to test whether the Mr 42 000 species did actu-
ally constitute a latent — but activatable reservoir of
proteolytically active cathepsin B, we treated a series of
synovial fluid samples with pepsin, essentially accord-
ing to the protocols described in previous work (23, 24).
Figure 3 records the levels of these latent activities.
From this figure it can be appreciated that all of the
rheumatoid arthritis-syriovial samples possess latent ca-
thepsin B-like activity. When this activation Step was
carried out in the absence öf pepsin, but using the same
buffer system (0.1 mol/1 glycine/HCl, pH 3-0), no ad.
ditional activity was generated. This would tend to ex-
clude the possibility that the Mr 42 000 band is ä cathep-
sin L precursor, since these species are known to be
efficiently activated by mild acid treatment alone (35,
36, 37). Additionally, the fact that this pepsin^generated
activity could cleave Cbz-Arg^Arg-NH-Mec, also streng-
thens our assertion that the MT 42 000 protein is a precur-
sor of cathepsin B and not of cathepsin L, since the latter
is incapable of eleaving this fluorogenic Substrate (20).
The inability of the 42 000 species to hydrolyse the
fluorogenic Substrate Cbz^Arg-Arg-NH-Mec, but yet iri-
1600
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Fig. 3 Levels of latent cathepsirOB-like activity in östeoarthritic
(*). and rheumatoid arthritic (·) synovial fluids.
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corporate the biotinylated affinity label, appeared, at
first sight, to represent something of a dichotomy. How-
ever, we also have observed just such behaviour with
the pepsin activatable, latent cathepsin B-like species
produced by human breast cancer cells in culture (15),
and a recent report on the incorporation of an 125I-radio-
labelled epoxide derivative N-(2S,3S)-3-trans-ethoxy-
carbonyloxirane-2-carbonyl-Z,-tyrosine benzyl ester into
the catalytically inactive prepro form of papain (38),
corroborates our observations and would suggest that
the proforms of the papain superfamily of cysteine pro-
teinases do possess some inherent chemical reactivity
towards certain active-site-directed affinity labels.
Therefore, we would offer the Suggestion that rheuma-
toid arthritic synovial fluids not only contain active ca-
thepsin B, but also a reservoir of a latent and activat-
able proform.
The molecular aspects of the pepsin-activation Step were
then analysed using the Western blotting protocols de-
scribed above; figure 2 records the results of some of
I these studies. From this figure it can be seen that the
i higher molecular mass band (MT 42000) disappears
; when the sample is treated with pepsin and then läbelled
with the biotinylated inhibitor (flg. 2, lane 4). In light of
our studies carried out on the human breast cancer cell-
associated cathepsin B mentioned above (15), we had
expected to find that this decrease in the Mr 42 000 form
would be accompanied by a corresponding increase in
the 29 000 species; but this was not the case. Rather,
it was noted that a new species was generated of Mr
20000. We presume that this is the species that is re-
sponsible for the 'additional' turnover of Cbz-Arg-Arg-
NH-Mec that is observed uppn pepsin treatment of the
samples.
Iminunological characterisation of cathepsin
B-like species
In order to further the case for the presence of a cathep-
sin B4ike species in synovial fluid, immunological
araalysis of samples iiot exposed to the biotinylated
probe was carried out. Probing of such samples with
anti-(cathepsiii B) antibodies gave results ^exactly com-
parable to those with the biotinylated probe, thus we
were again able to detect the two major bands of appar^·
ent MT 42 000 and 29 000 (fig. 2, lane 2). Immunoblot-
ting of pepsin^activated synovial fluid samples also
yielded completely syminetrical results whfen compäred
to the biotinylated probe (fig. 2, lane 1) complete with
the generation of the new species Mr 20000. The detec-
tion and characterisation, üsing antibodies raised against
active human cathepsin B, of latent forms of the protein-
ase has been previously reported, malignant asoites cells
in culture aire known to produce a Mr 40 000 proform
of the enzyme which can be converted into a Mr 33 000
species by pepsin activation (24).
The absolute symmetry between the results of the label-
ling with the biotinylated probe and the anti-(cathepsin
B) antibodies, in combination with the lack of autocat-
alysis of the latent form in acidic medium alone, lends
further Support to our thesis that we are detecting a lat-
ent pepsin-activatable and an active form of cathepsin B.
Conclusions
1. By inference to Substrate specificity, inhibitor suscep-
tibility and molecular weight (MT 29 000) — a cathepsin
B-like species was shown to be present in the synovial
fluid of patients suffering from osteoarthritis and rheu-
matoid arthritis.
2. By steady state analysis significantly elevated levels
of cathepsin B-like activity were found in rheumatoid
arthritic synovial fluid when compäred to osteoarthritic
fluid — thus suggesting a possible role for this protein-
ase in arthritic disease coupled with possible diagnostic
potential.
3. TThe action of pepsin revealed the presence of ad-
ditional cathepsin B-like activity in both osteoarthritic
and rheumatoid arthritic synovial fluid by steady state
analysis.
4. Western blot analysis of synovial fluid revealed the
presence of a higher molecular weight band (MT 42 000)
— thought to be a pepsin-activatable form of cathepsin
B and possibly responsible for the additional activity
observed in the pepsin steady state assay.
5. Immunoblotting of fluid samples not treated with the
biotinylated probe, using anti-(cathepsin B) antibodies,
yielded completely symmetrical results when compäred
to the Western blots using the probe, both before and
after pepsin treatment. Thus lending further support to
the thesis that we have detected a latent but pepsin-activ-
atable and an active form of cathepsin B in synovial
fluid.
6. In this wofk we have demonstrated the utilisation of
the recently developed biotinylated affinity label Bioti-
nyl-Phe-Ala-Diazomethane (Bio-Phe-Ala-CHN2) for the
detection of an active and a pepsin-activatable form of
a cathepsin B-like enzyme in diseased synovial fluid.
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